No Data
No Data
Le VitaFlow Liberty De CardioFlow Obtient Le Marquage CE-MDR De L'Union Européenne, Ce Qui Fait Progresser Son Expansion À L'échelle Mondiale
SHANGHAI, 18 juin 2024 /PRNewswire/ -- MicroPort CardioFlow Medtech Corporation (CardioFlow) (code boursier : 02160.HK) a récemment annoncé que son dispositif d'implantation de valve aortique trans
Are Investors Undervaluing MicroPort Scientific Corporation (HKG:853) By 22%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, MicroPort Scientific fair value estimate is HK$8.21 MicroPort Scientific is estimated to be 22% undervalued based on current share price of H
CardioFlow's VitaFlow Liberty Granted EU CE-MDR Mark, Advancing Global Expansion Roadmap
SHANGHAI, June 17, 2024 /PRNewswire/ -- MicroPort CardioFlow Medtech Corporation (CardioFlow) (Stock Code: 02160.HK) recently announced that its self-developed second-generation transcatheter aortic
HK Stock Market's unusual movement: Microport (00853) rose more than 4%, recently completed the redemption of 700 million US dollars convertible bonds.
Microport (00853) rose more than 4%. As of press time, it has risen by 4.38%, to HKD 6.44, with a turnover of HKD 43,503,400.
Citigroup rates Microport as a "buy" and lowers the target price to HKD 21.
Citigroup's research report states that based on Microport's (00853) management's latest guidance and recent sales trends, the bank has adjusted its earnings per share forecast. It is expected that earnings per share will increase by 59.4% in 2024 and by 43% in 2025 to reflect the company's strict cost control trend. The target price has been lowered from HKD 25 to HKD 21 to reflect the lower valuation of the heart valve business, with a buy rating.
MicroPort Scientific Redeems $700 Million Convertible Bonds Ahead of 2026 Maturity
MicroPort Scientific (HKG:0853) has fully redeemed and canceled its $700 million zero-coupon convertible bonds ahead of their maturity in 2026, according to a Wednesday filing with the Hong Kong Excha
No Data